Company / Net Income
IOVANCE BIOTHERAPEUTICS, INC. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$391.0M
FY2025
5-year range
-$444.0M / -$342.3M
FY2021-FY2025
Trend
-5.1%
vs FY2024
Sector context
#193 of 216
Health Care
What the data says
IOVANCE BIOTHERAPEUTICS, INC.'s net income of -$391M is lower than 89% of companies in the Health Care sector (FY2025). Improved from -$444M to -$391M over the past 2 years.
Based on SEC 10-K filings.
-$391M in FY2025.
Improved from -$444M to -$391M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 216This company -$391.0M Sector average $454.1M
▼
-186.1% below sector average
Key checks
Key Insights
- In FY2025, net income decreased 5.1% year-over-year.
- Ranks #193 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2016.
- Lowest net income in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.05 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$391.0M | -5.1% |
| FY2024 | -$372.2M | +16.2% |
| FY2023 | -$444.0M | -12.2% |
| FY2022 | -$395.9M | -15.7% |
| FY2021 | -$342.3M | -31.8% |
| FY2020 | -$259.6M | -31.4% |
| FY2019 | -$197.6M | -59.9% |
| FY2018 | -$123.6M | -34.2% |
| FY2017 | -$92.1M | -665.0% |
| FY2016 | -$12.0M | +52.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026